Editorial
Immunotherapy: remember the host
Translational Lung Cancer Research
2023;
12
(12)
:2366-2369
.
(26 December 2023)
Original Article
Cathepsin detection to identify malignant cells during robotic pulmonary resection
Translational Lung Cancer Research
2023;
12
(12)
:2370-2380
.
(26 December 2023)
Comparison of different maintenance regimens following first-line immunochemotherapy for advanced non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(12)
:2381-2391
.
(26 December 2023)
A collection of multiregistry data on patients at high risk of lung cancer—a Danish retrospective cohort study of nearly 40,000 patients
Translational Lung Cancer Research
2023;
12
(12)
:2392-2411
.
(26 December 2023)
Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?
Translational Lung Cancer Research
2023;
12
(12)
:2412-2426
.
(26 December 2023)
Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis
Translational Lung Cancer Research
2023;
12
(12)
:2427-2439
.
(26 December 2023)
Clinical characteristics and progression of pre-/minimally invasive lung adenocarcinoma harboring ALK or RET rearrangements: a retrospective cohort study
Translational Lung Cancer Research
2023;
12
(12)
:2440-2447
.
(26 December 2023)
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2023;
12
(12)
:2448-2459
.
(26 December 2023)
Serum-based biomarkers associated with lung cancer risk and cause-specific mortality in the German randomized Lung Cancer Screening Intervention (LUSI) trial
Translational Lung Cancer Research
2023;
12
(12)
:2460-2475
.
(26 December 2023)
Prognostic value and immune regulatory role of dynamin 1-like in lung adenocarcinoma
Translational Lung Cancer Research
2023;
12
(12)
:2476-2493
.
(26 December 2023)
Deep learning-assisted development and validation of an algorithm for predicting the growth of persistent pure ground-glass nodules
Translational Lung Cancer Research
2023;
12
(12)
:2494-2504
.
(26 December 2023)
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study
Translational Lung Cancer Research
2023;
12
(12)
:2505-2519
.
(26 December 2023)
Exosomal ITGB6 from dormant lung adenocarcinoma cells activates cancer-associated fibroblasts by KLF10 positive feedback loop and the TGF-β pathway
Translational Lung Cancer Research
2023;
12
(12)
:2520-2537
.
(26 December 2023)
Case Report: iMDT Corner
An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: a case report
Translational Lung Cancer Research
2023;
12
(12)
:2538-2549
.
(26 December 2023)
Case Report
Tract creation with a 25-gauge needle for convex endobronchial ultrasound-guided core biopsy in intrapulmonary lesions adjacent to bronchi: three case reports
Translational Lung Cancer Research
2023;
12
(12)
:2550-2557
.
(26 December 2023)
Combinatorial therapy is a safe and durable treatment option in ALK-rearranged non-small cell lung cancer with an acquired MET exon 14 skipping mutation mediated resistance to alectinib: a case report
Translational Lung Cancer Research
2023;
12
(12)
:2558-2564
.
(26 December 2023)
Editorial Commentary
Can liquid biopsy dynamics stratify patients with small cell lung cancer?
Translational Lung Cancer Research
2023;
12
(12)
:2565-2569
.
(26 December 2023)
eIF4A dependency: the hidden key to unlock KRAS mutant non-small cell lung cancer’s vulnerability
Translational Lung Cancer Research
2023;
12
(12)
:2570-2575
.
(26 December 2023)
